LUCY vs MGRX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LUCY exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While the company shows strong top-line revenue growth of 39% and a consistent track record of beating earnings estimates, these are overshadowed by a catastrophic profit margin of -285.20% and a 5-year price collapse of 99.1%. The high current ratio (9.03) suggests a temporary liquidity cushion, but the overall trajectory remains highly speculative and fundamentally unstable.
MGRX exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -1576.40%. Despite a low Price-to-Book ratio of 0.35, the company is experiencing consistent revenue contraction (-10.30% YoY) and massive long-term value destruction, with a 5-year price decline of 99.3%. The lack of analyst coverage and bearish insider activity further signal a lack of confidence in the company's viability.
Compare Another Pair
Related Comparisons
LUCY vs MGRX: Head-to-Head Comparison
This page compares Lucyd, Inc (LUCY) and Mangoceuticals, Inc. (MGRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.